• Korean Journal of Optics and Photonics
• /
• v.25 no.3
• /
• pp.131-136
• /
• 2014

In this paper we have implemented a temperature-insensitive polarimetric fiber strain sensor based on a Sagnac birefringence interferometer composed of a short polarization-maintaining photonic crystal fiber (PM-PCF), a 3-dB fiber coupler, and polarization controllers. The PM-PCF used as a sensor head was 2 cm long, which is the shortest length for a sensing element compared to other polarimetric fiber strain sensors using a PM-PCF. The proposed sensor showed a strain sensitivity of ${\sim}0.87pm/{\mu}{\varepsilon}$ with a strain measurement range from 0 to $8m{\varepsilon}$. The temperature sensitivity was also investigated and measured as approximately $-12pm/^{\circ}C$, when ambient temperature changed from 30 to $100^{\circ}C$. This temperature sensitivity is about 82 times smaller than that of conventional polarization-maintaining fiber (approximately $-990pm/^{\circ}C$). In particular, from a practical perspective we have experimentally and theoretically confirmed that the wavelength selected for the indicator dip location does not make a significant difference in the strain sensitivity.

• Microbiology and Biotechnology Letters
• /
• v.37 no.4
• /
• pp.377-382
• /
• 2009

Viral safety is an important prerequisite for clinical preparations of all biopharmaceuticals derived from plasma, cell lines, or tissues of human or animal origin. To ensure the safety, implementation of multiple viral clearance (inactivation and/or removal) steps has been highly recommended for manufacturing of biopharmaceuticals. Of the possible viral clearance strategies, Ultraviolet-C (UVC) irradiation has been known as an effective viral inactivating method. However it has been dismissed by biopharmaceutical industry as a result of the potential for protein damage and the difficulty in delivering uniform doses. Recently a continuous flow UVC reactor (UVivatec) was developed to provide highly efficient mixing and maximize virus exposure to the UV light. In order to investigate the effectiveness of UVivatec to inactivate viruses without causing significant protein damage, the feasibility of the UVC irradiation process was studied with a commercial therapeutic protein. Recovery yield in the optimized condition of $3,000\;J/m^2$ irradiation was more than 98%. The efficacy and robustness of the UVC reactor was evaluated with regard to the inactivation of human immunodeficiency virus (HIV), hepatitis A virus (HAV), bovine herpes virus (BHV), bovine viral diarrhea virus (BVDV), porcine parvovirus (PPV), bovine parvovirus (BPV), minute virus of mice (MVM), reovirus type 3 (REO), and bovine parainfluenza virus type 3 (BPIV). Non enveloped viruses (HAV, PPV, BPV, MVM, and REO) were completely inactivated to undetectable levels by $3,000\;J/m^2$ irradiation. Enveloped viruses such as HIV, BVDV, and BPIV were completely inactivated to undetectable levels. However BHV was incompletely inactivated with slight residual infectivity remaining even after $3,000\;J/m^2$ irradiation. The log reduction factors achieved by UVC irradiation were ${\geq}3.89$ for HIV, ${\geq}5.27$ for HAV, 5.29 for BHV, ${\geq}5.96$ for BVDV, ${\geq}4.37$ for PPV, ${\geq}3.55$ for BPV, ${\geq}3.51$ for MVM, ${\geq}4.20$ for REO, and ${\geq}4.15$ for BPIV. These results indicate that UVC irradiation using UVivatec was very effective and robust in inactivating all the viruses tested.